Ranibizumab in Preproliferative (Ischemic) Central Retinal Vein Occlusion

Brown, David M.; Wykoff, Charles C.; Wong, Tien P.; Mariani, Angeline F.; Croft, Daniel E.; Schuetzle, Karri L.

doi:10.1097/iae.0000000000000191

Cited by 90 publications

(73 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It is also important to notice that in our study, treatment with ranibizumab did not prevent the development of retinal neovascularization and rubeosis. This was also reported in a recent paper [29]. Therefore, the role of ranibizumab in preventing progression of ischemia and subsequent development of neovascular disease must be further addressed.…”

Section: Discussionmentioning

confidence: 99%

Treatment of Retinal Vein Occlusion with Ranibizumab in Clinical Practice: Longer-Term Results and Predictive Factors of Functional Outcome

et al. 2015

View full text Add to dashboard Cite

Purpose: To evaluate long-term results and predictors of efficacy in patients with macular edema due to retinal vein occlusion (RVO) treated with intravitreal ranibizumab in a clinical practice setting. Methods: The clinical records of patients with a minimum follow-up of 3 years were retrospectively analyzed. Sixteen eyes with branch RVO (BRVO) and 16 with central RVO (CRVO) were included. All patients performed cross-sectional evaluation with best-corrected visual acuity (BCVA), spectral domain optical coherence tomography and fluorescein angiography. The foveal avascular zone (FAZ) was assessed and microstructural morphology of the retina was characterized. Results: Follow- up was 42.9 ± 9.0 and 44.8 ± 8.0 months in the CRVO and BRVO groups, respectively. Patients with CRVO received on average 6.9 injections, with a final VA gain of 8.3 ± 15.0 letters (p = 0.05). BRVO eyes had on average 5.9 injections, with a final VA gain of 1.6 ± 21.0 letters (p > 0.05). The FAZ area remained stable in both groups (p > 0.05). Baseline BCVA and disruption of the retinal pigment epithelium (RPE) were predictors of final BCVA (p = 0.001 and 0.011, respectively). Conclusion: Although functional outcomes were inferior to those reported in clinical trials, ranibizumab was satisfactory in the long-term treatment of macular edema secondary to RVO and was not associated with increased macular ischemia. Final BCVA depends on baseline BCVA and RPE integrity.

show abstract

Section: Discussionmentioning

confidence: 99%

Treatment of Retinal Vein Occlusion with Ranibizumab in Clinical Practice: Longer-Term Results and Predictive Factors of Functional Outcome

et al. 2015

View full text Add to dashboard Cite

show abstract

“…26,27 In addition, we did not estimate nonperfusion areas quantitatively. When using the LSFG methodology, it is important to remember that the MBR is only able to provide relative and not absolute values for the blood velocity.…”

Section: Discussionmentioning

confidence: 99%

Retinal Blood Flow Correlates to Aqueous Vascular Endothelial Growth Factor in Central Retinal Vein Occlusion

Yamada

Suzuma

Matsumoto

et al. 2015

Retina

View full text Add to dashboard Cite

Results: Fluorescein angiography found 20 ischemic and 25 non-ischemic type eyes. Aqueous VEGF concentration in the ischemic type was significantly higher than that in the non-ischemic type (P = 0.01). Arteriovenous passage time was significantly correlated to the logarithm of the aqueous VEGF concentration (P = 0.0001). MBR of the affected eye / MBR of the unaffected eye of the ischemic type was significantly lower than the non-ischemic type (P = 0.039). Additionally, MBR was significantly correlated both to the logarithm of the aqueous VEGF concentration (P < 0.0001) and to the arteriovenous passage time (P = 0.0001).

show abstract

“…This progression is time dependent, with a progression rate of 33% within 3 years [19] . Neovascular complications may arise in 50% of patients whose eyes have ischemic CRVO in a 4-year period, despite treatment with anti-VEGF [20] . Raised intraocular pressure and raised erythrocyte sedimentation can be found in CRVO [7,8,17] .…”

Section: L a S S I F I C A T I O N O F R E T I N A L V E I N Occlusionmentioning

confidence: 99%

Definition and Classification of Retinal Vein Occlusion

Kolář

2016

International Journal of Ophthalmic Research

View full text Add to dashboard Cite

Ranibizumab in Preproliferative (Ischemic) Central Retinal Vein Occlusion

Cited by 90 publications

References 10 publications

Treatment of Retinal Vein Occlusion with Ranibizumab in Clinical Practice: Longer-Term Results and Predictive Factors of Functional Outcome

Treatment of Retinal Vein Occlusion with Ranibizumab in Clinical Practice: Longer-Term Results and Predictive Factors of Functional Outcome

Retinal Blood Flow Correlates to Aqueous Vascular Endothelial Growth Factor in Central Retinal Vein Occlusion

Definition and Classification of Retinal Vein Occlusion

Contact Info

Product

Resources

About